Free Trial
Biren Amin

Biren Amin Analyst Performance

Sr. Research Analyst at Piper Sandler

Biren Amin is a stock analyst at Piper Sandler focused in the medical sector, covering 45 publicly traded companies. Over the past year, Biren Amin has issued 18 stock ratings, including buy and hold recommendations. While full access to Biren Amin's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Biren Amin's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
152 Last 11 Years
Buy Recommendations
84.87% 129 Buy Ratings
Companies Covered
45 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy84.9%129 ratings
Hold14.5%22 ratings
Sell0.7%1 ratings

Out of 152 total stock ratings issued by Biren Amin at Piper Sandler, the majority (84.9%) have been Buy recommendations, followed by 14.5% Hold and 0.7% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
45 companies

Biren Amin, an analyst at Piper Sandler, currently covers 45 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
41 companies
91.1%
Miscellaneous
4 companies
8.9%

Biren Amin of Piper Sandler specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
19 companies
42.2%
PHARMACEUTICAL PREPARATIONS
9 companies
20.0%
MED - DRUGS
5 companies
11.1%
Miscellaneous
4 companies
8.9%
BIOTECHNOLOGY
3 companies
6.7%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
2 companies
4.4%
MED - GENERIC DRG
1 company
2.2%
COMMERCIAL PHYSICAL RESEARCH
1 company
2.2%
COMPUTER INTEGRATED SYSTEMS DESIGN
1 company
2.2%

About Biren Amin

Biren Amin is a managing director and senior research analyst on the healthcare equity research team covering biotechnology companies. Prior to joining Piper Sandler, Amin served as the chief financial officer and chief strategy officer at Pyramid Biosciences, a private biotechnology company, where he was responsible for investor relations, capital raising and leading business development activities including monitoring key competitors for therapeutics targeting solid tumors. Before Pyramid Biosciences, Amin served as the chief financial officer at Immuneering Corporation, a public clinical-stage oncology company. He previously spent 10 years at Jefferies Financial Group Inc. covering small and mid-cap biotechnology companies focused on oncology, central nervous system disorders, ophthalmology and rare diseases. Prior to Jefferies Financial Group Inc., Amin spent seven years in various equity research roles covering the biotechnology sector. Amin graduated from University of the Sciences with a bachelor's degree in pharmacy. He received his master's degree from Long Island University and his Master of Business Administration degree from the Leonard Stern School of New York University.
Follow on LinkedIn

Biren Amin's Ratings History at Piper Sandler

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
7/29/2025Boost Price Target$13.86$15.00Neutral
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
7/23/2025Set Price Target$2.57$3.00Neutral
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
7/23/2025Initiated Coverage$2.77$3.00Neutral
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
7/21/2025Lower Price Target$13.79$18.00Neutral
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
7/14/2025Boost Price Target$46.47$68.00Overweight
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
7/10/2025Initiated Coverage$1.62$6.00Overweight
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
6/26/2025Reiterated Rating$0.64$4.00Overweight
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
6/16/2025Downgrade$36.18$36.00Neutral
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
5/16/2025Lower Price Target$2.84$17.00Overweight
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
5/14/2025Lower Price Target$0.93$7.00Overweight
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
5/7/2025Lower Price Target$38.37$70.00Overweight
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
4/30/2025Boost Price Target$38.50$63.00Overweight
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
4/21/2025Lower Price Target$53.62$110.00Overweight
LENZ Therapeutics, Inc. stock logo
LENZ
LENZ Therapeutics
4/14/2025Initiated Coverage$21.95$51.00Overweight
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
3/31/2025Initiated Coverage$14.59$38.00Overweight
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
3/21/2025Downgrade$0.28$0.70Neutral
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
2/19/2025Initiated Coverage$3.17$12.00Overweight
CARGO Therapeutics, Inc. stock logo
CRGX
CARGO Therapeutics
1/30/2025Downgrade$13.19$4.00Neutral